In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of adults with moderate-to-severe systemic lupus erythematosus (SLE). The drug’s ...

Columnist Candace Semien praises the community's ability to survive and thrive without guilt while living with lupus.

Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

Controlling cardiovascular risk factors and maintaining long-term disease remission mitigated the increased risk for ...

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...

The presence of antiarrestin autoantibodies among patients with SLE is associated with an increased risk of developing HCQ-related retinal toxicity.

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) ...

Atherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...